Local ablative therapies and the effect on antitumor immune responses in pancreatic cancer–A review
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease, projected to rank as
the second most prevalent cause of cancer-related mortality by 2030. Despite significant …
the second most prevalent cause of cancer-related mortality by 2030. Despite significant …
Local Ablative Therapy Associated with Immunotherapy in Locally Advanced Pancreatic Cancer: A Solution to Overcome the Double Trouble?—A Comprehensive …
J Garnier, O Turrini, AS Chretien, D Olive - Journal of clinical medicine, 2022 - mdpi.com
Pancreatic ductal adenocarcinoma (PDAC) remains a major killer and is a challenging
clinical research issue with abysmal survival due to unsatisfactory therapeutic efficacy. Two …
clinical research issue with abysmal survival due to unsatisfactory therapeutic efficacy. Two …
Locally advanced pancreatic cancer: percutaneous management using ablation, brachytherapy, intra-arterial chemotherapy, and intra-tumoral immunotherapy
FEF Timmer, B Geboers, S Nieuwenhuizen… - Current oncology …, 2021 - Springer
Abstract Purpose of Review Pancreatic ductal adenocarcinoma (PDAC) is one of the most
aggressive neoplasms, bearing a terrible prognosis. Stage III tumors, also known as locally …
aggressive neoplasms, bearing a terrible prognosis. Stage III tumors, also known as locally …
The landmark series: locally advanced pancreatic cancer and ablative therapy options
Locally advanced pancreatic cancer (LAPC) is a challenging disease to treat. There is
consensus that systemic chemotherapy should be the first line of therapy for most patients …
consensus that systemic chemotherapy should be the first line of therapy for most patients …
[HTML][HTML] Needle-guided ablation of locally advanced pancreatic cancer: cytoreduction or immunomodulation by in vivo vaccination?
B Geboers, AH Ruarus, S Nieuwenhuizen… - Chinese clinical …, 2019 - cco.amegroups.org
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive forms of cancer
with a dismal prognosis. About a third of all patients with pancreatic cancer present with …
with a dismal prognosis. About a third of all patients with pancreatic cancer present with …
Advances in pancreatic ductal adenocarcinoma treatment
EM Anderson, S Thomassian, J Gong, A Hendifar… - Cancers, 2021 - mdpi.com
Simple Summary Pancreatic cancer remains one of the most challenging malignancies to
treat with standard approaches. Emerging treatment approaches incorporating innovative …
treat with standard approaches. Emerging treatment approaches incorporating innovative …
The use of radiofrequency ablation in pancreatic cancer in the midst of the dawn of immuno-oncology
I Reccia, J Kumar, N Habib, M Sodergren - Medical oncology, 2018 - Springer
Despite significant improvement in treatment, the prognosis of pancreatic ductal
adenocarcinoma remains poor as the biology of the tumour affects survival even when a …
adenocarcinoma remains poor as the biology of the tumour affects survival even when a …
New therapeutic targets in pancreatic cancer
E Lai, M Puzzoni, P Ziranu, A Pretta, V Impera… - Cancer treatment …, 2019 - Elsevier
Pancreatic ductal adenocarcinoma (PDAC) is associated with poor survival. Of all newly
diagnosed patients, only about 20% can benefit from a potentially curative surgical …
diagnosed patients, only about 20% can benefit from a potentially curative surgical …
The next frontier in pancreatic cancer: Targeting the tumor immune milieu and molecular pathways
C Yin, A Alqahtani, MS Noel - Cancers, 2022 - mdpi.com
Simple Summary Pancreatic ductal adenocarcinoma (PDAC) has a notoriously bad
prognosis due to its high mortality and lack of good therapies. Chemotherapy is the current …
prognosis due to its high mortality and lack of good therapies. Chemotherapy is the current …
Immunologic Strategies in Pancreatic Cancer: Making Cold Tumors Hot
NA Ullman, PR Burchard, RF Dunne… - Journal of Clinical …, 2022 - ascopubs.org
The rising incidence and persistent dismal 5-year overall survival of pancreatic ductal
adenocarcinoma (PDAC) highlight the need for new effective systemic therapies …
adenocarcinoma (PDAC) highlight the need for new effective systemic therapies …